- Home
- BCV vs BDTX Comparison
BCV vs BDTX Comparison
Compare BCV & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCV | BDTX |
|---|---|---|
| Founded | 1971 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.4M | 148.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BCV | BDTX |
|---|---|---|
| Price | $23.72 | $2.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.40 |
| AVG Volume (30 Days) | 26.3K | ★ 876.9K |
| Earning Date | 01-01-0001 | 03-05-2026 |
| Dividend Yield | ★ 8.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.38 |
| Revenue | N/A | ★ $70,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.03 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.09 | $1.20 |
| 52 Week High | $18.11 | $4.94 |
Technical Indicators
Market Signals| Indicator | BCV | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.89 | 36.66 |
| Support Level | $23.01 | $2.17 |
| Resistance Level | $24.55 | $2.37 |
| Average True Range (ATR) | 0.30 | 0.14 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 47.40 | 16.96 |
Price Performance
Historical ComparisonAbout BCV Bancroft Fund Ltd.
Bancroft Fund Ltd is a diversified closed-end management company. It operates as a closed-ended equity mutual fund. The funds' main objective is to provide income and potential for capital appreciation. With the intent to achieve its objective, the company invests in convertible and equity securities. It invests across different industries such as Computer Software and Services, Energy and Utilities, Health Care among others.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.